544478-19-5
544478-19-5 結構式
基本信息
英文別名
MRS 1845N-PROPARGYLNITRENDIPENE
MRS-1845
MRS1845
MRS 1845
MRS 1845 >=95% (HPLC), solid
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-1-(2-propynyl)-3,5-pyridinedicarboxylicacidethylmethylester
1,4-DIHYDRO-2,6-DIMETHYL-4-(3-NITROPHENYL)-1-(2-PROPYNYL)-3,5-PYRIDINEDICARBOXYLIC ACID ETHYL, METHYL ESTER
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-1-(2-propyn-1-yl)-, 3-ethyl 5-methyl ester
物理化學性質(zhì)
沸點511.0±50.0 °C(Predicted)
密度1.238±0.06 g/cm3(Predicted)
儲存條件2-8°C
溶解度DMSO: 13 mg/mL at 60 °C, soluble
酸度系數(shù)(pKa)0.03±0.70(Predicted)
形態(tài)solid
顏色yellow
常見問題列表
生物活性
MRS1845 是一種選擇性鈣池調(diào)控鈣離子通道 (SOC) 抑制劑，IC50 為 1.7 μM。MRS1845 是一種 ORAI1 抑制劑。靶點
Ca 2+ channel
體外研究
Treatment with MRS1845 (10 μM) virtually disrupts the effects of β-glycerophosphate on store-operated Ca
2+
entry (SOCE).
MRS1845 (10 μM) significantly decreases SOCE and virtually abolishes the increase of SOCE following placental growth factor (PlGF) treatment.